Literature DB >> 21199372

A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population.

Bao-xia He1, Lei Shi, Jian Qiu, Liang Tao, Rui Li, Liang Yang, Shu-jin Zhao.   

Abstract

CYP3A4 is a major member of the cytochrome P450 (CYP) enzymes which play crucial roles in cardiovascular diseases. Recently, a novel polymorphism in the CYP3A4 gene, IVS10+12G>A, named CYP3A4*1G (rs2242480), has been identified. The aim of this study was to evaluate the potential relationship between the CYP3A4*1G allele and the susceptibility of coronary heart disease (CHD). A total of 628 individuals (322 unrelated patients with CHD and 306 age- and sex-matched healthy controls) were investigated in the study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used to identify CYP3A4*1G. We also analysed the functional significance of IVS10+12G>A using the dual-luciferase reporter assay. The results showed that the frequency of the CYP3A4*1G allele was 0.290 and the CYP3A4*1G/*1G genotype was 0.090 in the patients with CHD. The patients with the CYP3A4*1G/*1G genotype had higher CHD risk, with an odds ratio (OR) of 3.84 (p=0.025; 95% CI=1.32-12.65) after adjustment for conventional risk factors. A gender-dependent difference was also observed. The CYP3A4*1G/*1G frequency was significantly higher in female patients than in the controls (p=0.034, OR=3.02, 95% CI=1.04-8.70). Furthermore, the dual-luciferase reporter assay indicated that the A allele at IVS10+12G>A had a significantly higher transcriptional activity than the G allele. Our results imply that CYP3A4*1G contributes to the susceptibility of CHD in the Chinese Han population, which may be useful for the study of specific molecular pathogenesis for CHD.
© 2010 The Authors. Basic & Clinical Pharmacology & Toxicology © 2010 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21199372     DOI: 10.1111/j.1742-7843.2010.00657.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  17 in total

1.  Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.

Authors:  Joana Assis; Deolinda Pereira; Mónica Gomes; Dânia Marques; Inês Marques; Augusto Nogueira; Raquel Catarino; Rui Medeiros
Journal:  Int J Clin Exp Med       Date:  2013-08-01

2.  IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients.

Authors:  Mou-Ze Liu; Hai-Yan He; Yue-Li Zhang; Yong-Fang Hu; Fa-Zhong He; Jian-Quan Luo; Zhi-Ying Luo; Xiao-Ping Chen; Zhao-Qian Liu; Hong-Hao Zhou; Ming-Jie Shao; Ying-Zi Ming; Hua-Wen Xin; Wei Zhang
Journal:  Acta Pharmacol Sin       Date:  2017-01-23       Impact factor: 6.150

3.  Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.

Authors:  Xu Liu; Xi Huang; Shanshan Zhang; Fanglin Niu; Yongri Ouyang; Zhexing Shou; Jikui Liu
Journal:  Int J Clin Oncol       Date:  2018-09-14       Impact factor: 3.402

4.  Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.

Authors:  Floris Fauchet; Jean-Marc Treluyer; Silvia M Illamola; Claire Pressiat; Gabrielle Lui; Elodie Valade; Laurent Mandelbrot; Jerome Lechedanec; Sandrine Delmas; Stéphane Blanche; Josiane Warszawski; Saik Urien; Roland Tubiana; Déborah Hirt
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

5.  The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.

Authors:  Martha L Bustos; Steve N Caritis; Kathleen A Jablonski; Uma M Reddy; Yoram Sorokin; Tracy Manuck; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; Alan M Peaceman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan M Ramin
Journal:  Am J Obstet Gynecol       Date:  2017-05-15       Impact factor: 8.661

6.  The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.

Authors:  Steven Lane; Sameh Al-Zubiedi; Ellen Hatch; Ivan Matthews; Andrea L Jorgensen; Panos Deloukas; Ann K Daly; B Kevin Park; Leon Aarons; Kayode Ogungbenro; Farhad Kamali; Dyfrig Hughes; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

7.  Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and smoked meat intake, and breast cancer incidence.

Authors:  Humberto Parada; Susan E Steck; Rebecca J Cleveland; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella; Marilie D Gammon
Journal:  Ann Epidemiol       Date:  2016-11-25       Impact factor: 3.797

8.  Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.

Authors:  Marta Karaźniewicz-Łada; Dagmara Krzyżańska; Dorota Danielak; Janusz Rzeźniczak; Franciszek Główka; Marek Słomczyński; Paweł Burchardt
Journal:  Eur J Clin Pharmacol       Date:  2020-01-02       Impact factor: 2.953

9.  Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism.

Authors:  Joseph M Collins; Danxin Wang
Journal:  Pharmacogenet Genomics       Date:  2022-01-01       Impact factor: 2.089

10.  No association of a set of candidate genes on haloperidol side effects.

Authors:  Antonio Drago; Ina Giegling; Martin Schäfer; Annette M Hartmann; Hans-Jürgen Möller; Diana De Ronchi; Hans H Stassen; Alessandro Serretti; Dan Rujescu
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.